AMLX - Amylyx Pharmaceuticals

-

$undefined

N/A

(N/A)

Amylyx Pharmaceuticals NASDAQ:AMLX Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Location: | Website: www.amylyx.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-128.3M

Cash

309.8M

Avg Qtr Burn

-14.67M

Short % of Float

3.18%

Insider Ownership

14.35%

Institutional Own.

86.49%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Relyvrio (AMX0035) Details
Amyotrophic lateral sclerosis

Approved

Update

AMX0035 Details
Progressive supranuclear palsy

Phase 3

Data readout

Relyvrio (AMX0035) Details
Amyotrophic lateral sclerosis

Phase 3

Update

Avexitide Details
Hyperinsulinism, Post-Bariatric Hypoglycemia, Congenital Hyperinsulinism

Phase 3

Initiation

AMX0035 Details
Wolfram syndrome

Big Mover™

Susp. Mover™

Phase 2

Data readout

AMX0035 Details
Alzheimer's disease

Phase 2

Update

AMX0114 Details
Amyotrophic lateral sclerosis

Phase 1

Initiation